An objective response rate of 48.2% was observed with ifinatamab deruxtecan in these previously treated patients Discussions with global regulatory authorities underway SCLC is aggressive and ...

Immix Biopharma announced significant results from its NEXICART-2 Phase 1/2 clinical trial of NXC-201 at the ASCO 2025 conference, achieving a complete response (CR) rate of 70% in patients with ...

ORLANDO -- For triple-class exposed relapsed or refractory multiple myeloma with extramedullary disease (EMD), a combination of talquetamab (Talvey) and teclistamab (Tecvayli) achieved high response ...

Iovance Biotherapeutics announced promising results from a real-world study of its commercially available Amtagvi® (lifileucel) for treating advanced melanoma in patients previously treated with ...

Breyanzi achieved a 95.5% response rate in relapsed or refractory marginal zone lymphoma, with 62.1% complete responses and 88.6% ongoing at 24 months. The therapy maintained a consistent safety ...

Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without ...

In a paper initially prepared for the planning meeting for this review, Peytchev (2013) observes that drawing “unbiased inference from probability-based surveys relies on the collection of data from ...